AMRN Amarin Corp

RNS Number:0303B
Amarin Corporation Plc
27 July 2007


          AMARIN ANNOUNCES SECOND QUARTER 2007 RESULTS CONFERENCE CALL


                     Management to provide pipeline update


LONDON, United Kingdom, July 27, 2007 Amarin Corporation plc (NASDAQ: AMRN)
("Amarin" or "Company") today announced that it will be discussing its second
quarter 2007 results and providing a pipeline update in a conference call at
8.30 a.m. Eastern time/1.30 p.m. British summer time on Wednesday, August 1,
2007. Rick Stewart, Chief Executive Officer, Declan Doogan, President Research
and Development and Alan Cooke, President and Chief Financial Officer, can be
heard by dialling (800) 968 7995 (tollfree) in the U.S. or +1 (706) 679 8403
(toll) elsewhere. Conference ID 10049924.
The call will also be webcast live and a link will be on the company's website
at www.amarincorp.com. Information on the company's website is not part of this
release.

For those who cannot listen to the live broadcast, a replay will be available
shortly after the conference call in the link on the company's website
www.amarincorp.com or by dialling (800) 642 1687 (tollfree) in the U.S. or +1
(706) 645 9291 (toll) elsewhere, and entering access code 10049924.


About Amarin


Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system. Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.

Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.

Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.

For press releases and other corporate information, visit the Amarin website at
www.amarincorp.com. Information on our website does not form part of this press
release.


Contacts:

Amarin +44 (0) 207 907 2442
Rick Stewart Chief Executive Officer
Alan Cooke President and Chief Financial Officer
investor.relations@amarincorp.com

Investors:

Lippert/Heilshorn & Associates, Inc. +1 212 838 3777
Kim Golodetz
Anne Marie Fields

Media:

Powerscourt +44 (0) 207 250 1446
Rory Godson
Sarah Daly

Disclosure Notice:


The information contained in this document is as of July 27, 2007. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: the success of Amarin's research and development activities,
decisions by regulatory authorities regarding whether and when to approve
Amarin's drug applications, as well as their decisions regarding labeling and
other matters that could affect the commercial potential of Amarin's products;
the speed with which regulatory authorizations, pricing approvals and product
launches may be achieved; the success with which developed products may be
commercialized; competitive developments affecting Amarin's products under
development; the effect of possible domestic and foreign legislation or
regulatory action affecting, among other things, pharmaceutical pricing and
reimbursement, including under Medicaid and Medicare in the United States, and
involuntary approval of prescription medicines for over-the-counter use;
Amarin's ability to protect its patents and other intellectual property; claims
and concerns that may arise regarding the safety or efficacy of Amarin's product
candidates; governmental laws and regulations affecting Amarin's operations,
including those affecting taxation; Amarin's ability to maintain sufficient cash
and other liquid resources to meet its operating requirements; general changes
in International and US generally accepted accounting principles; growth in
costs and expenses; and the impact of acquisitions, divestitures and other
unusual items. A further list and description of these risks, uncertainties and
other matters can be found in Amarin's Annual Report on Form 20-F for the fiscal
year ended December 31, 2006 and in its Reports of Foreign Issuer on Form 6-K
furnished to the SEC.


Ends.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NOREDLFLDDBLBBF

Amarin (LSE:AMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024